Can-Fite BioPharma Ltd. Registration statement for securities of certain foreign private issuers

Finance Income (Tables)

12 Months Ended

Dec. 31, 2018

	Year ended December 31,
	2018			2017			2016
	USD
Finance expenses:

Bank commissions	$	18		$	28		$	27
Financial expenses from defined benefit plans					-			12
Interest expenses from IFRS 15 implementation		427			-			-
Net loss from exchange rate fluctuations		115			588			16
Other loss from long-term investment revaluation		644			5			-

		1,204			621			55
Finance income:

Interest income on bank deposits		(51	)		(69	)		(89	)
Net change in fair value warrants exercisable into shares		-			(564	)		(285	)

		(51	)		(633	)		(374	)

	$	1,153		$	(12	)	$	(319	)